New Potential Biomarker and Therapeutic Target for ALS Patients

New data revealing a link between the LDL receptor-related protein 4 (LRP4) and amyotrophic lateral sclerosis (ALS) was presented during the 67th American Academy of Neurology Annual Meeting in April 2015. The presentation was entitled “LRP4 antibodies are frequent in serum and CSF from amyotrophic lateral sclerosis patients”. ALS is…

In a new study entitled “Neural population dynamics in human motor cortex during movements in people with ALS” researchers at Stanford University shed light on how the brain controls muscle movement. Their findings may help accelerate the development of prosthetic devices for patients with motor neuron…

Researchers at the University of Alberta and the National Institute for Nanotechnology in Canada recently reported new insights into the misfolding process of proteins from a normal structure to a disease state characteristic of degenerative disorders. The study entitled “Protein misfolding occurs by slow diffusion…

In a recent study published in the journal eLife, a team of researchers at Stanford University was able to identify a group of neurons that work together and fire in complex rhythms to send movement signals to muscles. “We hope to apply these findings to create prosthetic…

Researchers at Columbia University, New York recently published in the journal Cell Reports their findings on eight different master regulators involved in amyotrophic lateral sclerosis (ALS) neurodegeneration in mouse models. The study is entitled “The Regulatory Machinery of Neurodegeneration in In Vitro Models…

The ALS Association together with the ALS Finding a Cure Foundation recently announced a $3 million funding for two Phase II clinical trials via the ALS Accelerated Therapeutics (ALS ACT) initiative, a project focused on accelerating the discovery of new ALS therapies in part by funding pilot clinical…

The ALS Association has recently awarded a $1.5 million grant to investigator Robert G. Miller, MD, to be invested in the study of a potential treatment for amyotrophic lateral sclerosis (ALS), called NP001. Dr. Miller is studying Neuraltus Pharmaceuticals’ investigational therapy which will now enter a phase 2 clinical trial.

Genervon Biopharmaceuticals recently announced it has filed a patent application based on data from the Phase 2A clinical trial (GALS001 study, NCT01854294) assessing the company’s product GM604 as a therapy for amyotrophic lateral sclerosis (ALS) and data from a single ALS compassionate patient study (GALS-C). ALS is a…

Researchers at the University of California at San Francisco (UCSF) recently revealed new insights into the pathogenesis of neurodegenerative diseases. The study, published in The Journal of Neuroscience, is entitled “The Progranulin Cleavage Products, Granulins, Exacerbate TDP-43 Toxicity and Increase TDP-43 Levels”. Mutations in…

Chris Rosati, who was diagnosed with amyotrophic lateral sclerosis (ALS) in November 2010, challenged the ALS Association to publicly declare that a cure for the disease will be found in the next six years. In an emotional video addressed to the association’s CEO Barbara Newhouse, Mr. Rosati explained…